GLP-1 Maintenance Dose: Titration Schedule, Plateaus, and What Happens If You Miss a Dose

What Is a Maintenance Dose for GLP-1 Medications?

The maintenance dose is the dose at which a patient stays after completing titration, the point where therapeutic effect is sustained without further scheduled increases. For semaglutide 2.4 mg (Wegovy), the FDA-approved maintenance dose is 2.4 mg subcutaneously once weekly, as specified in the current product label [1]. For tirzepatide (Zepbound), the FDA-approved maintenance range is 10 mg or 15 mg subcutaneously once weekly, with the prescriber choosing based on tolerability and response [2].

The distinction between a titration dose and a maintenance dose matters clinically. During titration, the body is adapting to the drug's GLP-1 receptor agonism (and GIP agonism, in tirzepatide's case), which drives the GI side-effect burden. The maintenance phase is where the majority of total weight loss accumulates. In STEP-1 (N=1,961), participants did not reach their nadir weight at 16 weeks when they arrived at 2.4 mg. They continued losing weight through week 68, achieving a mean 14.9% body-weight reduction versus 2.4% in the placebo group (P<0.001) [3]. The maintenance dose is not a ceiling. It is the floor from which continued benefit is built.

For type 2 diabetes management with semaglutide (Ozempic), the maintenance dose is typically 1.0 mg once weekly, with an option to escalate to 2.0 mg if glycemic targets are not met. STEP-2 (N=1,210 adults with obesity and T2D) showed that 2.4 mg semaglutide produced a 9.6% weight reduction versus 3.4% with placebo at 68 weeks, with HbA1c falling by 1.6 percentage points in the 2.4 mg arm [4].

The Titration Schedule: Step by Step

Titration exists to reduce nausea, vomiting, and early dropout. Moving too fast through dose steps is the single most avoidable cause of discontinuation in GLP-1 therapy.

Semaglutide (Wegovy) titration schedule per FDA label [1]:

| Week | Dose | |------|------| | 1, 4 | 0.25 mg once weekly | | 5, 8 | 0.5 mg once weekly | | 9, 12 | 1.0 mg once weekly | | 13, 16 | 1.7 mg once weekly | | 17+ | 2.4 mg once weekly (maintenance) |

Tirzepatide (Zepbound) titration schedule per FDA label [2]:

| Week | Dose | |------|------| | 1, 4 | 2.5 mg once weekly | | 5, 8 | 5 mg once weekly | | 9, 12 | 7.5 mg once weekly | | 13, 16 | 10 mg once weekly | | 17, 20 | 12.5 mg once weekly | | 21+ | 15 mg once weekly (maximum maintenance) |

Patients who cannot tolerate a dose step may stay at the previous dose for an additional 4 weeks before attempting the increase again. This is explicitly permitted by both labels. Forcing escalation through intolerable side effects generates dropout without generating additional benefit.

STEP-3 (N=611) added intensive behavioral therapy on top of semaglutide 2.4 mg and found a mean 16.0% weight reduction at 68 weeks versus 5.7% in the placebo-plus-behavioral-therapy arm [5]. The behavioral component mattered, but the drug's contribution was independent and additive.

How Long Do You Stay on the Maintenance Dose?

The evidence strongly favors indefinite continuation. GLP-1 receptor agonists work through ongoing receptor signaling. When that signaling stops, appetite regulation and energy expenditure revert toward baseline.

STEP-5 followed 304 participants on semaglutide 2.4 mg for 104 weeks. The mean weight reduction was 15.2% at two years, and adverse-event rates did not increase with extended exposure [6]. No new safety signals emerged during the second year of maintenance dosing.

The withdrawal data are even more instructive. In STEP-4, participants who reached 20 weeks of semaglutide treatment and were then randomized to placebo regained an average of 6.9% of body weight by week 48, while those continuing semaglutide lost an additional 7.9%. The net difference was 14.8 percentage points [as cited in the STEP-5 analysis] [6].

SURMOUNT-4 (tirzepatide, N=783) replicated this pattern. Participants who completed 36 weeks of tirzepatide and were then switched to placebo regained 14% of body weight over the following 52 weeks, while those continuing tirzepatide lost an additional 5.5% [7]. The SURMOUNT-4 authors wrote: "Continued tirzepatide treatment led to additional weight loss of 5.5%, whereas placebo led to weight regain of 14.0% over the 52-week randomized period."

The AACE/ACE obesity clinical practice guidelines describe obesity as a chronic disease requiring long-term management, stating: "Anti-obesity medications should be used as part of a comprehensive lifestyle intervention program and continued indefinitely if the patient benefits and is not experiencing significant adverse effects" [8].

Plateau: What It Is and What to Do

A weight-loss plateau on a GLP-1 agent is defined as less than 1% body-weight change over 12 consecutive weeks at the maximum tolerated dose. Plateaus are not treatment failures. They reflect physiological adaptation, including metabolic rate downregulation that occurs with any significant caloric deficit.

The first question when a plateau occurs is whether the patient is truly at their maximum tolerated dose. Some patients spend months at 1.7 mg semaglutide without ever attempting 2.4 mg because of residual GI concerns. A dose increase from 1.7 mg to 2.4 mg produces additional weight loss in a meaningful proportion of patients, as the STEP-1 titration curve shows continued loss through week 68 in those who reached full dose [3].

The second question is concurrent behavior. STEP-3 showed that semaglutide combined with intensive behavioral therapy (defined as 30 counseling visits over 68 weeks) outperformed the drug alone. If a patient is plateauing and has not engaged with dietary guidance, that represents an addressable gap.

Switching from semaglutide to tirzepatide is a documented clinical option for plateau management. SURMOUNT-3 (N=579) enrolled participants who had already achieved at least 5% weight loss through intensive lifestyle intervention and then added tirzepatide 15 mg, producing an additional 18.4% weight reduction at 72 weeks [9]. This does not replicate a direct switch scenario, but it demonstrates the additive capacity of tirzepatide in patients who have already used behavioral approaches.

STEP-8 (N=338) provides the most direct head-to-head comparison: semaglutide 2.4 mg produced 15.8% weight loss at 68 weeks versus 6.4% with liraglutide 3.0 mg [10]. If a patient is plateauing on liraglutide, this trial supports a step-up to semaglutide as evidence-based rather than experimental.

HealthRX Plateau Decision Framework (for prescriber use):

1. Confirm the patient has been at maximum tolerated dose for at least 12 weeks.
2. Review injection technique and storage conditions (semaglutide must be refrigerated; room temperature <30°C acceptable for up to 28 days per label).
3. Assess dietary adherence using a 3-day food record reviewed by a registered dietitian.
4. If steps 1, 3 are confirmed and plateau persists: escalate to maximum dose if not already there, or discuss transition to tirzepatide.
5. If already at maximum dose of tirzepatide with confirmed plateau after 12 weeks: evaluate for contributing medications (corticosteroids, antipsychotics, insulin secretagogues) and refer to bariatric medicine specialist.

What Happens If You Miss a Dose?

Missing a single dose of a weekly GLP-1 agent does not require dose adjustment but does require a protocol decision based on how much time has elapsed.

Per the Wegovy FDA label [1]:

• If 5 days or fewer have passed since the missed dose: inject as soon as possible, then resume the regular weekly schedule.
• If more than 5 days have passed: skip the missed dose entirely and take the next dose on the regularly scheduled day.

The Zepbound label follows the same 5-day window [2]. Never double-dose to compensate for a missed injection. Injecting two doses within a few days substantially increases the risk of nausea, vomiting, and hypoglycemia in patients taking concomitant insulin or sulfonylureas.

One or two missed doses at the maintenance level do not require restarting the titration schedule. However, patients who have been off therapy for four or more weeks, due to supply disruptions, insurance issues, or other factors, may benefit from re-titrating from a lower dose to avoid resurgent GI side effects. This re-titration decision belongs to the prescribing clinician.

Patients on semaglutide should keep a consistent injection day. Changing the day of the week is permitted as long as doses remain at least 2 days apart. This flexibility accommodates travel and schedule changes without compromising efficacy.

Microdosing GLP-1 Medications: What the Evidence Actually Shows

Microdosing refers to using below-label doses of GLP-1 agents, typically compounded semaglutide at doses ranging from 0.1 mg to 0.5 mg weekly, as a maintenance or long-term strategy distinct from the standard titration protocol. No published randomized controlled trial has evaluated below-label maintenance dosing for weight management outcomes.

The 0.25 mg starting dose used in Wegovy's titration is itself a sub-therapeutic dose. The FDA label describes it as "for treatment initiation only to reduce gastrointestinal side effects," not as a dose intended to produce weight loss [1]. The pharmacodynamic dose-response curve for semaglutide is steep: the difference in weight loss between 1.0 mg and 2.4 mg is approximately 4, 5 percentage points of body weight based on STEP-1 data [3].

Some patients and clinicians use reduced doses after reaching goal weight as a strategy to minimize side effects and cost while preserving some benefit. This approach has biological plausibility because GLP-1 receptor agonism operates on a partial agonism curve, meaning lower doses still produce some receptor occupancy. The dose that maintains a given weight may be lower than the dose required to produce ongoing weight loss.

The FDA does not currently have approved labeling for a "weight-maintenance" dose lower than 2.4 mg for semaglutide or lower than 10 mg for tirzepatide. Any below-label dosing represents off-label use and should be discussed explicitly with the patient, documented in the chart, and paired with close monitoring of weight trajectory every 4 to 8 weeks.

Compounded semaglutide from 503B outsourcing facilities has been widely used during the Wegovy shortage period. The FDA placed both semaglutide and tirzepatide on the resolved shortage list in 2024, which affects the legal status of compounding for these agents. Prescribers should confirm current FDA shortage status before prescribing compounded alternatives.

Cardiovascular Outcomes at the Maintenance Dose

The SELECT trial (N=17,604 adults with obesity or overweight and established cardiovascular disease, no diabetes) found that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo over a mean follow-up of 39.8 months (hazard ratio 0.80; 95% CI 0.72, 0.90; P<0.001) [11]. This was a prespecified primary endpoint, not a secondary observation.

The trial enrolled patients at the 2.4 mg maintenance dose after a standard titration period. Cardiovascular benefit appeared early, with separation of the MACE curves beginning before week 52. This finding has directly informed clinical practice guidelines: the American Heart Association and ACC now recognize GLP-1 receptor agonists with proven cardiovascular benefit as preferred agents in patients with both obesity and atherosclerotic cardiovascular disease.

SURMOUNT-1 (N=2,539) showed that tirzepatide 15 mg produced a mean 20.9% body-weight reduction at 72 weeks versus 3.1% placebo (P<0.001), the largest mean weight loss reported in any Phase 3 obesity pharmacotherapy trial to date [12]. Cardiovascular outcome data for tirzepatide in the dedicated SURMOUNT-CVOT trial are pending.

Dosing in Special Populations

Renal impairment does not require dose adjustment for semaglutide 2.4 mg per the Wegovy label, but prescribers should use caution in severe renal impairment given the risk of dehydration from GI side effects contributing to acute kidney injury [1]. The same precaution applies to tirzepatide [2].

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), based on rodent carcinogenicity data. This contraindication applies at all doses, including maintenance [1].

Patients over 65 do not require dose adjustment. STEP-1 included participants across a wide age range, and subgroup analyses showed consistent weight-loss effects in older adults, though GI tolerability may require a slower titration pace in practice.

SURMOUNT-2 (N=938 adults with T2D and obesity) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.58 percentage points and body weight by 13.9% at 72 weeks versus placebo [13]. For patients managing both T2D and obesity, the maintenance dose serves dual metabolic goals simultaneously.